1 Min Read
Sept 30 (Reuters) - Abbvie Inc :
* AbbVie’s investigational HCV regimen receives U.S. FDA Breakthrough Therapy Designation Source text for Eikon: Further company coverage: ;))
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.